| Prev Close | 55.41 |
| Day Low/High | 55.76 / 56.69 |
| 52 Wk Low/High | 53.22 / 69.75 |
Bristol-Myers Squibb Company (BMY)
56.32
NYSE
| Exchange | NYSE |
| Shares Outstanding | 2219.64B |
| Market Cap | 122.99B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
I've Used a Strategy of Trade-Offs With 2 Biotech Stocks
I tend to only use this strategy to a great extent when I have a negative or neutral view on the overall market.
Glimmers of Hope in the Biotech Realm as M&A Activity Picks Up
A recent trio of acquisition deals indicates the doldrums in the sector may be over.
Don't Own Merck Stock Yet? Here's My Prescription
I am in this one for the medium to long term.
A Bristol-Myers Bounce? Here's How I'd Play It
Keep in mind earnings are scheduled for Oct. 27 along with a $0.49 dividend on Sept. 30.
3 Big Pharma Buys for Dividend Investors
In a market with elevated valuations and low yields, we see pharmaceutical stocks as a respite from both.
Would-Be Buyers Should Wait for a Dip in Bullish Prothena
The shares of the under-the-radar biotech have had a strong run in recent months, so traders might want to watch for a pullback to buy.
Pfizer's Charts Suggest a Strong Rally Ahead
Here are our latest price targets.
Jim Cramer: The Drug Cos. Are at Full Strength
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
Resilience? Stagflation Signs, Nvidia Action, Fed Hawks on Deck, Booster Rockets
A wall of liquidity seems to absorb every dip. But there are also enough reasons to be ever vigilant.
Jim Cramer: To Every Market Sector, Turn, Turn, Turn
To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...
China 'Rules', Defense Stocks, Infrastructure Package, FOMC, Earnings
What if Beijing plays the power game with foreign firms reliant upon Chinese revenue, Chinese labor, or simply Chinese economic growth?
Bristol-Myers Squibb Makes Its Upside Breakout
Here's what traders and investors should do next.
Here Is Something Cathie Wood and I Agree On
* The attractiveness of Coinbase Speaking of ARK Invest, the ETF complex has purchased Coinbase on nearly three-quarters of the days it has been public. All transactions below are dated May 20: FUND Direction Ticker CUSIP Name Shares % of ETF ARKF ...
2 Biotech Stocks That Appear Undervalued Based on Their Prospects
Agenus Inc. and uniQure N.V. recently have announced positive news developments that should boost their long-term prospects.
Jim Cramer: Here's What Can Go Higher
Let's look at the companies that can go up, and the ones that can't.
Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market
Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'
Economics for Dummies, Fed Recap, Fun With Jobs Math, Amazon, Buying ServiceNow
The differences in approach between the two most basic strategies for how to grow an economy are as stark as the division they cause among economists.
A Blue Chip Healthcare Stock for Growth And Yield
Bristol-Myers offers a terrific combination of yield, dividend safety, and dividend growth for income-focused investors.
Is Bristol-Myers Squibb Finally Ready for a Breakout?
Prices have rallied from early March and are in a position to test their January highs.
Looking at Bristol-Myers Again as the Quants Downgrade It
At current levels BMY is sort-of in no man's land - not bullish and not bearish.
Here Are 2 Biotechs That Posted Strong Earnings
Exelixis and Ultragenyx Pharmaceutical are cash rich mid-caps that don't look overbought.
Turn of the Worm, Treasury Curve, Manchin's Might, Trading Microsoft, Spotify
There is a point where if longer-dated yields move high enough, defensive-minded investors will be drawn from equities to debt securities.
Jim Cramer: Looking for Gold? Go With Science
A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.
Bristol-Myers Squibb Could Finally Make Its Move
Traders should stay long and consider increasing their exposure.
How to Play Emergent BioSolutions Right Now
A correction in EBS could soon set up an attractive opportunity.
The Week That Was, Q4 Earnings Expectations, Key Investor and Healthcare Events
This Friday several banks begin the unofficial kickoff of 'earnings season'.
How I'm Playing Astra-Zeneca on Vaccine and Acquisition News
I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.
